Press Release

MediLink Therapeutics Announces Strategic Collaboration, Worldwide License Agreement With BioNTech

October 12, 2023

Palo Alto – October 12, 2023 – Cooley advised MediLink Therapeutics, a clinical-stage biotech company focused on developing globally competitive conjugated drugs, on its strategic research collaboration and worldwide license agreement with BioNTech. The Cooley team advising MediLink was led by partner Lila Hope and associate Chen Chen, with valuable support from special counsel Jennifer Raab.

Under the terms of the agreement, MediLink will grant BioNTech exclusive global rights for the development, manufacturing and commercialization of one of MediLink’s antibody-drug conjugate candidate assets, excluding mainland China and the Hong Kong and Macau special administrative regions. In exchange, BioNTech will provide MediLink with an upfront payment of $70 million, and additional development, regulatory and commercial milestone payments potentially totaling more than $1 billion.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has over 1,300 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of nearly 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.